THE Therapeutic Goods Administration (TGA) has advised there is a shortage of Ritalin and Artige immediate-release tablets, with a shortage of Ritalin LA capsules anticipated.
This is in addition to current shortages of Concerta and Methylphenidate-Teva XR products, which are expected to last until the end of the year.
The Ritalin LA capsule shortage is predicted from 21 Apr 2025 for the 30 mg strength, and from May, June and July 2025 for the other strengths.
These medicines are used to treat attention deficit hyperactivity disorder (ADHD).
"We acknowledge the concerns and difficulties caused by such shortages, especially due to the specific requirements for prescribing and dispensing methylphenidate hydrochloride," the TGA stated.
"We hope this notification will give patients and prescribers the opportunity to plan ahead.
"We urge patients who are affected by these shortages to speak with their pharmacist about their supply of medicine.
"We also suggest patients consult with their prescribers early about their treatment plan, as they may need a new prescription."
The TGA noted that another methylphenidate medicine remains available, and it has also approved overseas-registered Concerta tablets for supply.
Pharmacists can order these alternative products and supply them to patients using existing prescriptions for Concerta.
However, overseas-registered section 19A Concerta tablets are not PBS-subsidised, the TGA pointed out.
Other medicines approved to treat ADHD are also available, and pharmacists should advise patients to contact their doctor if their prescribed medicine is unavailable and substitutable alternatives are either inappropriate or unavailable.
More information is HERE. KB
The above article was sent to subscribers in Pharmacy Daily's issue from 09 Apr 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Apr 25
